Daniel Janney General Information
Mr. Daniel Janney serves as Managing Director at Alta Partners. He also serves as Board Member at DEM BioPharma. His focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities. He serves as Board Member at Be Biopharma and ImmuneID. He joined Alta immediately following the firm's founding in 1996 and was a co-founder of the Alta BioPharma effort. He focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. He is or has served on the board of directors of a number of companies, including Alba Therapeutics, Allakos, DiscoveRx, Esperion Therapeutics, Lithera, Prolacta Bioscience, and ViroBay. In addition, he led Alta's investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems, and Mako Surgical. He served as a Board Member at Evolve BioSystems and Sutro Biopharma. Prior to joining Alta, he was a senior investment banker at Montgomery Securities, focusing on life sciences companies. He is also a member of The President's Council of the Gladstone Institutes. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles. He also serves as a Board Member of Novome Biotechnologies. He also serves as Board Member at Lassen Therapeutics. He has been investing in life sciences companies for more than 20 years. He joined Alta Partners at its founding and is a Managing Director. His focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 32 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. He is currently on the board of directors of several public and private companies, including Esperion Therapeutics, Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve. In addition, he led Alta's investments in Astex Pharmaceuticals (acquired by Supergen), Collective (acquired by Medimmune), ChemGenex (acquired by Cephalon), CoTherix (acquired by Actelion), DeUnity Health (acquired by United Health), Dynavax, Endonetics (acquired by Medtronic), Ilex Oncology (acquired by Millennium Pharmaceuticals), InterMune (acquired by Roche), LJL Biosystems (acquired by Molecular Devices), Mako Surgical (acquired by Stryker) and Triangle Pharmaceuticals (acquired by Gilead). He also serves as Chairman of the Board of Trustees at the California Academy of Science.